Back to top

Analyst Blog

Savient Pharmaceuticals, Inc. recently announced that Louis Ferrari has been entrusted the role of President and Chief Executive Officer (CEO) by the company’s board of directors. Mr. Ferrari possesses over 30 years of experience in the pharmaceutical industry.

He held the position of Executive Vice President, President North American Commercial Operations at Savient and is integrally involved in the rollout of Savient’s key drug, Krystexxa, and development of the company’s growth strategies. Prior to joining Savient in February 2011, Louis Ferrari was employed at Johnson and Johnson (JNJ - Analyst Report) as Vice President of oncology and nephrology, sales and marketing.

He will replace interim CEO, David Y. Norton. Both David Y. Norton and Mr. Ferrari will continue to be members of Savient’s board of directors.

Meanwhile, the company also announced job cuts of approximately 35% (effective from September 10, 2012) as part of a restructuring initiative. Savient plans to restructure its field force. The restructured field force will comprise 35 key account managers and 3 regional business directors.

The restructuring initiative, aimed at improving operating efficiencies, is expected to yield $56 million in operating expense savings annually by 2013 with annualized first quarter 2012 operating expenses as a base.

In 2012, the company expects to recognize operating expense savings of approximately $6.5 million. These restructuring initiatives are expected to cost approximately $4.7 million of which $3.6 million will be incurred in 2012.

Recommendation

We currently have a Neutral recommendation on Savient. The stock carries a Zacks #3 Rank (Hold rating) in the short run.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
CTPARTNERS… CTP 13.33 +3.49%
SAIA INC SAIA 45.65 +1.00%
VASCO DATA… VDSI 13.57 +0.67%
AMEDISYS IN… AMED 20.18 +0.10%
FIRSTSERVIC… FSRV 55.66 -0.13%